Synbiotics Corp. Reintroduces Witness FeLV

***

Health/Medical Writers / Business Editors SAN DIEGO--(BUSINESS WIRE)--SBIO-- Synbiotics Corp. (Pink Sheets:SBIO) today announced that the USDA has approved their Witness(R) FeLV antigen test kit. The kit rejoins Synbiotics' Witness(R) line of veterinary diagnostics that includes the Witness(R) HW canine heartworm antigen test and the Witness(R) Relaxin pregnancy test for dogs and cats. Synbiotics has been a leader in feline leukemia virus diagnostics since 1987 with ViraCHEK(R)/FeLV, Synbiotics' feline leukemia virus ELISA microwell test, as one of the premier FeLV diagnostics available today. Witness(R) FeLV utilizes Rapid Immuno Migration (RIM(R)) technology, similar to that found in home pregnancy test kits, to simplify the testing procedure and eliminate the wash step required by ELISA tests. Its small sample size -- only 0.05 ml of whole blood, plasma or serum -- makes it ideal for testing young kittens or uncooperative adults. "Witness(R) tests, thanks to their accuracy, speed and simplicity, have achieved a significant level of success both in the U.S. and international markets," according to Paul Hays, President and COO of Synbiotics. "We are pleased that our new relationship with a local company, with a proven record of innovation in the development and manufacture of high performance immunoassays, has enabled us to resume the supply of Witness(R) FeLV. Our FeLV product will soon be followed by Witness(R) CPV canine parvovirus fecal antigen test kit." Witness(R) FeLV is available as a 10-test kit from Synbiotics' Distributors. Synbiotics Corp. develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, Synbiotics manufactures and distributes its products through its operations in San Diego and Lyon, France. For information on Synbiotics and its products, visit the company's Web site at www.synbiotics.com. With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including the need to restructure the company's matured but unpaid bank loan, competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the seasonality of major portions of the company's business and other risks set forth in Synbiotics Corp.'s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2003. These forward-looking statements represent Synbiotics Corp.'s judgment as of the date of the release. Synbiotics Corp. disclaims, however, any intent or obligation to update these forward-looking statements. KEYWORD: INTERNATIONAL EUROPE CALIFORNIA INDUSTRY KEYWORD: MANUFACTURING MEDICAL MEDICAL DEVICES PRODUCT SOURCE: Synbiotics Corp. CONTACT INFORMATION: Synbiotics Corp. Paul R. Hays, President & COO 858-451-3771, ext. 1401 paulh@synbiotics.com or Keith A. Butler, Vice President and CFO 858-451-3771, ext. 1413 keith@synbiotics.com

------------------
You Must Adapt To Your Opportunities And Weaknesses. You Can Use A Variety Of Approaches And Still Have A Consistant Result. - Sun Tzu, "The Art Of War"

Do Da Due.....But Be Damn Quick About It. - Dardadog, "Da Art Of Daytrading"